HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA, Industry To Testify At House Cosmetics Hearing

This article was originally published in The Rose Sheet

Executive Summary

A March 27 hearing titled “Examining the Current State of Cosmetics” will likely focus more on the future of cosmetics regulation in the U.S. CFSAN director Michael Landa is slated to testify, as are representatives from the Personal Care Products Council and small businesses.

You may also be interested in...



Rep. Lance, Council Work To Generate Support For Cosmetics Bill

New Jersey Rep. Leonard Lance will discuss his cosmetics bill, the Cosmetic Safety Amendments Act, with L’Oreal employees at a news conference on May 7. The bill is also backed by the Personal Care Products Council, which is working to gain legislative support from both parties.

Cosmetics Legislative Plans Vie In Congress

Rep. Frank Pallone, D-N.J., introduces the Cosmetic Safety Enhancement Act of 2012 before March 27th’s Energy and Commerce hearing on cosmetics regulation. Representatives Jan Schakowsky and Ed Markey push for their Safe Cosmetics Act of 2011, while Rep. Leonard Lance, R-N.J., intends to introduce his own cosmetics plan.

Campaign For Safe Cosmetics Requests Congressional Hearing

A request from the Campaign for Safe Cosmetics has prompted House Energy and Commerce Committee leadership to schedule a March 21 hearing to discuss cosmetics legislation, the activist group says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel